J&J hunts for a Rybrevant label add just months after rare lung cancer approval

J&J won’t be first to market with a treatment for non-small lung cancer patients who have a rare mutation called METex14. But now, the company’s taking a deeper look at some Phase I data in the hopes of positioning its drug Rybrevant as an option for those who become resistant to currently available MET inhibitors.